488 related articles for article (PubMed ID: 15578371)
1. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.
Antinori A; Larussa D; Cingolani A; Lorenzini P; Bossolasco S; Finazzi MG; Bongiovanni M; Guaraldi G; Grisetti S; Vigo B; Gigli B; Mariano A; Dalle Nogare ER; De Marco M; Moretti F; Corsi P; Abrescia N; Rellecati P; Castagna A; Mussini C; Ammassari A; Cinque P; d'Arminio Monforte A;
Clin Infect Dis; 2004 Dec; 39(11):1681-91. PubMed ID: 15578371
[TBL] [Abstract][Full Text] [Related]
2. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
3. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.
Abgrall S; Rabaud C; Costagliola D;
Clin Infect Dis; 2001 Nov; 33(10):1747-55. PubMed ID: 11595976
[TBL] [Abstract][Full Text] [Related]
5. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
Nasti G; Talamini R; Antinori A; Martellotta F; Jacchetti G; Chiodo F; Ballardini G; Stoppini L; Di Perri G; Mena M; Tavio M; Vaccher E; D'Arminio Monforte A; Tirelli U;
J Clin Oncol; 2003 Aug; 21(15):2876-82. PubMed ID: 12885804
[TBL] [Abstract][Full Text] [Related]
6. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
Mocroft A; Ledergerber B; Viard JP; Staszewski S; Murphy M; Chiesi A; Horban A; Hansen AB; Phillips AN; Lundgren JD;
J Infect Dis; 2004 Dec; 190(11):1947-56. PubMed ID: 15529259
[TBL] [Abstract][Full Text] [Related]
7. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses.
Hoffmann C; Ernst M; Meyer P; Wolf E; Rosenkranz T; Plettenberg A; Stoehr A; Horst HA; Marienfeld K; Lange C
Clin Microbiol Infect; 2007 May; 13(5):510-5. PubMed ID: 17298486
[TBL] [Abstract][Full Text] [Related]
8. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival.
Diamond C; Taylor TH; Aboumrad T; Anton-Culver H
Cancer; 2006 Jan; 106(1):128-35. PubMed ID: 16329140
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation and outcome of toxoplasmic encephalitis in patients with human immunodeficiency virus type 1 infection.
Ho YC; Sun HY; Chen MY; Hsieh SM; Sheng WH; Chang SC
J Microbiol Immunol Infect; 2008 Oct; 41(5):386-92. PubMed ID: 19122919
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Miro JM; Lopez JC; Podzamczer D; Peña JM; Alberdi JC; Martínez E; Domingo P; Cosin J; Claramonte X; Arribas JR; Santín M; Ribera E;
Clin Infect Dis; 2006 Jul; 43(1):79-89. PubMed ID: 16758422
[TBL] [Abstract][Full Text] [Related]
12. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.
Zeller V; Truffot C; Agher R; Bossi P; Tubiana R; Caumes E; Jouan M; Bricaire F; Katlama C
Clin Infect Dis; 2002 Mar; 34(5):662-7. PubMed ID: 11810599
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM
J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
Bonnet F; Balestre E; Thiébaut R; Morlat P; Pellegrin JL; Neau D; Dabis F;
Clin Infect Dis; 2006 Feb; 42(3):411-7. PubMed ID: 16392091
[TBL] [Abstract][Full Text] [Related]
16. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.
Robotin MC; Law MG; Milliken S; Goldstein D; Garsia RJ; Dolan GM; Kaldor JM; Grulich AE
HIV Med; 2004 Sep; 5(5):377-84. PubMed ID: 15369514
[TBL] [Abstract][Full Text] [Related]
18. Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence.
Gaitan Cepeda LA; Ceballos Salobreña A; López Ortega K; Arzate Mora N; Jiménez Soriano Y
Med Oral Patol Oral Cir Bucal; 2008 Feb; 13(2):E85-93. PubMed ID: 18223535
[TBL] [Abstract][Full Text] [Related]
19. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
[TBL] [Abstract][Full Text] [Related]
20. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
